Suggested remit - To appraise the clinical and cost effectiveness of intravenous zanamivir within its marketing authorisation for treating influenza in hospital
Please note this appraisal has now been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process STA Standard
ID number 1196

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 January 2024 Discontinued. Please note this appraisal has now been discontinued.
30 January 2018 - 27 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual